Connor, Clark & Lunn Investment Management (CC&L)
APGE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Apogee Therapeutics APGE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$966K Sell
11,481
-1,208
-10% -$87.7K ﹤0.01% 1167
2025
Q4 		$958K Buy
+12,689
New +$799K ﹤0.01% 1145

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s APGE Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Apogee Therapeutics (APGE) stake by 9.5% in Q1 2026, selling an estimated $87.7K and leaving 11,481 shares worth $966K. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in APGE in Q4 2025 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 11,481 shares of Apogee Therapeutics worth $966K as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,208 Apogee Therapeutics shares in Q1 2026, an estimated $87.7K.
  • Apogee Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1167 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.